Cell cycle progression data on human skin cancer cells with anticancer synthetic peptide LTX-315 treatment.

Santa-González GA, Patiño-González E, Manrique-Moreno M

Data in brief19 Mar 2020Cited by 6 (Europe PMC)

PMID32258289PMCIDPMC7118296DOI10.1016/j.dib.2020.105443PepBankPUB-32258289

Summary

Skin cancer, including melanoma and non-melanoma (NMSC), represents the most common type of malignancy in the white population [1]. The incidence rate of melanoma is increasing worldwide, while the associated mortality remains stable. On the other hand, the incidence of NMSC varies widely [1,2]. Camilio and collaborators recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, commercialized as Oncopore™ [3,4]. Despite various studies demonstrating the efficiency of LTX-315 therapy in inducing cancer cell death, the effects on cell cycle progression of this antitumoral peptide are poorly understood. In this research, we present data about the effect of LTX-315 on the cell cycle of two skin cancer cell lines: epidermoid carcinoma cells (A431) and melanoma cells (A375); as well as on an immortalized normal keratinocyte cell line, HaCaT. Additionally, its cytotoxicity on the cells was determined by measuring the uptake of propidium iodide, in order to establish its relationship with cell cycle progression. The analysed data obtained by flow cytometry show different cell cycle distributions in non-tumoral and skin cancer-derived cell lines in response to LTX-315 treatment. Non-tumoral cells showed a sub-G1 peak, while for tumoral cells there was a shift in the G1peak without producing an obvious distant and distinct sub-G1 peak. This data is in accordance with a major decrease in cell viability in non-cancer cells.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In non-tumoral keratinocytes, LTX‑315 treatment produced a sub-G1 peak.
In plain wordsIn cells, LTX‑315 produced a sub-G1 peak in non-tumoral keratinocytes.
Peptide
LTX-315
Outcome
IncreaseSub-G1 peak
Study
humann: not reported in source
HaCaT immortalized normal keratinocytes
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Non-tumoral cells showed a sub-G1 peak, while for tumoral cells there was a shift in the G1peak without producing an obvious distant and distinct sub-G1 peak.
1 context sentence(design, population, supporting numbers)
Summary · context
In this research, we present data about the effect of LTX-315 on the cell cycle of two skin cancer cell lines: epidermoid carcinoma cells (A431) and melanoma cells (A375); as well as on an immortalized normal keratinocyte cell line, HaCaT.
Show in the study text Report a problemFND-3225828901
02LabIn vitro (cells)Mechanism
In skin cancer cells, LTX‑315 shifted the G1 peak without an obvious distinct sub-G1 peak.
In plain wordsIn cells, LTX‑315 shifted the skin cancer cell G1 peak without an obvious distinct sub-G1 peak.
Peptide
LTX-315
Outcome
Not applicableG1 peak distribution
Study
humann: not reported in source
A431 and A375 skin cancer cells
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Non-tumoral cells showed a sub-G1 peak, while for tumoral cells there was a shift in the G1peak without producing an obvious distant and distinct sub-G1 peak.
1 context sentence(design, population, supporting numbers)
Summary · context
In this research, we present data about the effect of LTX-315 on the cell cycle of two skin cancer cell lines: epidermoid carcinoma cells (A431) and melanoma cells (A375); as well as on an immortalized normal keratinocyte cell line, HaCaT.
Show in the study text Report a problemFND-3225828902
03LabIn vitro (cells)Activity measurement
In non-cancer keratinocytes, LTX‑315 treatment was associated with a major decrease in cell viability.
In plain wordsIn cells, LTX‑315 treatment was associated with a major decrease in non-cancer cell survival.
Peptide
LTX-315
Outcome
DecreaseNon-cancer cell viability
Study
humann: not reported in source
HaCaT immortalized normal keratinocytes
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Source sentences
Summary
This data is in accordance with a major decrease in cell viability in non-cancer cells.
1 context sentence(design, population, supporting numbers)
Summary · context
In this research, we present data about the effect of LTX-315 on the cell cycle of two skin cancer cell lines: epidermoid carcinoma cells (A431) and melanoma cells (A375); as well as on an immortalized normal keratinocyte cell line, HaCaT.
Show in the study text Report a problemFND-3225828903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.